1 week ago
7
Dr. Xie Fangmin, founder, chairman, and CEO of Fangzhou commented, "At Fangzhou, we are dedicated to advancing domain-specific AI models which are able to solve real-world healthcare challenges while maintain the highest standards of safety and efficacy."
Comprehensive Safety Architecture
At the summit, Fangzhou's executive unveiled the Company's groundbreaking approach to ensuring medical AI accuracy and reliability. To address critical risks such as flawed symptom assessments or false drug information, Fangzhou has engineered an innovative three-tiered safety system. The security framework leverages a "robust knowledge database + multi-model collaboration + stringent safety controls," aiming to reduce hallucinations and mitigate risks by ensuring data source integrity, optimizing model training, and validating outputs.
Get the latest news
delivered to your inbox
Sign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.
Blueprint for Vertical AI Leadership
At the summit, Fangzhou proposed a two-tiered approach to accelerating Guangzhou's development of domain-specific AI expertise. On the R&D front, Fangzhou recommended strengthening interdisciplinary talent development in medical AI, fostering high-impact use cases, and accelerating technology commercialization. For industry deployment, the strategy should focus on bolstering infrastructure, emphasizing practical use cases, and fostering ecosystems, with targeted support for specialized and innovative companies.
AI-Powered Expansion and Forward-Looking Strategy
Fangzhou's expansion plans are closely tied to its implementation of AI models such as DeepSeek-V3 and strategic collaborations with Tencent Health and Tencent Cloud, aimed at advancing AI-enabled healthcare solutions. The Company intends to enhance its technological strength and accelerate the commercialization of its innovations, ultimately aiming to provide better experiences for both patients and users.
About Fangzhou Inc.
Fangzhou Inc. (06086.HK) is China's leading online chronic disease management platform, serving 49.2 million registered users and 223,000 physicians (as of December 31, 2024). The Company specializes in delivering tailored medical care and precision medicine solutions. For more information, visit https://investors.jianke.com.
About the Modern Industrial System Development Summit
The Modern Industrial System aims to establish Guangzhou as a hub for strategic sectors like AI and biotech by 2025. Vertical-specific models are prioritized under China's 2024 State Council AI guidelines to counter "homogeneous competition" in generic AI.
Media Contact
For further inquiries or interviews, please reach out to:
Xingwei Zhao Associate Director of Public Relations Email: [email protected]
Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements.
